| Aug 6 |
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
|
| Aug 1 |
Merus GAAP EPS of -$0.81 misses by $0.05, revenue of $7.33M misses by $1.11M
|
| Aug 1 |
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 1 |
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
|
| Aug 1 |
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
| Jul 29 |
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Jul 24 |
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
|
| Jul 12 |
Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%
|
| Jul 8 |
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
|
| Jul 1 |
Sector Update: Health Care Stocks Retreat Late Afternoon
|
